Why it matters: Pharmaceutical companies see promise in gene therapies and are willing to pay a large premium for them, but the treatments also come with record-high price tags. Spark has an $850,000 gene therapy to treat a rare eye condition, and a separate product is in the works for hemophilia.
Inside the White House with D.C.'s most wired reporter. Sign up for Mike Allen's Axios AM.
More stories loading.